Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study

View Full Paper
Ask AI
Bookmark
Share

Authors

OHOlivier HermineWJWojciech JurczakJFJoão Samuel de Holanda Farias

Discussion

Loading...

Member takes

Overview

Phase 1/2 study reveals 53.4% response rate in patients with R/R mantle cell lymphoma, indicating promising sonrotoclax benefits.

Key Points

  • The response rate in patients with relapsed mantle cell lymphoma reached 53.4%, showcasing sonrotoclax's efficacy in tough cases.
  • Following 125 enrolled patients, median duration of response was notable at 15.8 months with sonrotoclax at 320 mg.
  • In a phase 1/2 study design, treatment-emergent adverse events like neutropenia were monitored closely to assess safety.
  • Results support sonrotoclax as a potential treatment option, especially where traditional therapies have failed.

Cite This Study

Hermine et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8cahttps://doi.org/10.1182/blood-2025-663
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-1012025 · 1 citations
  2. 2Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma2025 · 3 citations
  3. 3Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study2025 · 1 citations
  4. 4Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study2025 · 1 citations
  5. 5Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients2025